Zoom Logo

Monkeypox: An Update on the Current Epidemic and Implications for HIV Programs - Gallery view
Sarah Dixon (she/her)
22:36
Sarah Dixon, FHI 360 HQ
erica hamilton
24:22
erica hamilton, FHI 360 HQ, Durham, NC
HP Laptop
24:25
Brohs Ou, Self learning from Cambodia.
Obinna Onuoha
24:42
Obinna OnuohaBreakthrough ACTION NigeriaHQ Abuja
Chris Beyrer
24:47
Chris Beyrer, Duke Global Health Institute
Bob Malley
24:59
Bob Malley Omaya-USAID, URC-Uganda
Endale Tilahun
25:06
Endale Tilahun, PSI/Eswatini
selly Ba
25:15
Selly BA , FHI360 Dakar , Senegal
Maria Cordova
25:25
Sofia Cordova, Population Services International - PSI, Guatemala
Jill Gay
25:26
Jill Gay, What Works Association
Christiana Laniyan
25:27
Christiana Laniyan, Global Fund NAHI Project, Nigeria
Sandeep Ghiya
25:34
Dr. Sandeep Ghiya | Independent Consultant | Mumbai, India
Jennifer Arney
25:36
Jennifer Arney, FHI 360, Washington DC
Anna Helland
25:37
Anna Helland, Johns Hopkins Center for Communication Programs
Mamotheba Busa
25:52
Mamotheba Busa form Master of Healing Foundation Lesotho LGBTIQ+
Gertrude Nunoo
25:55
Trudi Nunoo, FHI360 EpiC Ghana
Aung Zayar Paing
26:12
Aung Zayar Paing, Sr. Technical Advisor, EpiC Burma, FHI 360.
Sylvester Segbaya
26:16
Sylvester Segbaya, Johns Hopkins Center for Communication Programs, Ghana
Rebecca Dirks
26:21
Rebecca Dirks, FHI 360, Washington DC
Edward Subi
26:24
Edward Subi, Breakthrough Action Nigeria, Jos. Plateau State. Nigeria
Bethany Coomes
26:33
Bethany Coomes, FHI 360, NC (USA)
Sylvester Segbaya
26:59
Andrew Amenyo, Johns Hopkins Center for Communication Programs, Ghana
Anselmus Aristo Parut
27:05
Aristo Parut, Indonesia
John Macom
27:22
John Macom, FHI 360/EpiC, Phnom Penh, Cambodia
Sylvester Segbaya
27:24
Edward ADIMAZOYA, Johns Hopkins Center for Communication Programs, Ghana
Siripong Srichau
27:40
Arm Antony, APCOM, Thailand
Pat Sadate-Ngatchou
31:26
Pat Sadate-Ngatchou, FHI 360
Chris Akolo
32:01
Chris Akolo, FHI 360, Washington, DC
Barinaadaa Afirima
32:28
Afirima Barinaadaa, FHI360 Malawi
Dr.Christian Nkama
32:43
Christian Nkama ,FHI360 CDI
Sylvester Segbaya
33:15
Mavis Osafo, Johns Hopkins Center for Communications Program, Ghana
Mary Kariuki
33:40
Mary Kariuki FHI360
Shawn Aldridge
33:44
Shawn Aldridge, IntraHealth International
Sylvester Segbaya
34:31
VIVIAN ABIWU, JHU CPP, GHANA
Hally Mahler
35:43
Please add your questions for Stef and Deb here.
Bhagawan Shrestha
36:36
Bhagawan, FHI 360 Nepal
Shaundell Shipley
36:49
shaundell shipley, National AIDS Programme, GUYANA
Obinna Onuoha
37:31
On data coming from Nigeria, the NCDC is actively reporting cases on a weekly basis. An EOC meeting showed that total cases as of 4 September, in 2022, is 318 with 7 confirmed deaths so far.
Jill Gay
37:32
For Dr. Golstein - what are USAID's plans to distribute vaccines for Monkeypox, which seem to be unavailable.
Benjamin Phelps
37:35
B. Ryan Phelps here (Medical Officer at USAID). I am working with the interagency Global Monkeypox Response Team and we are gathering insights on what specifically is leading to the decrease in MPX cases within European and other settings without significant current vaccine coverage. If this leveling off is a result of behavior change and risk mitigation, what exactly led to that change? Social media campaigns? Word of mouth? Insights from this welcome. I can also be reached via email
Benjamin Phelps
39:55
Thank you for that response.
Bob Malley
40:03
Dear Deb, thanks for the wonderful presentation; this interventions/response seems more to the KI/PP! Also not sure if the major mode of transmission is sexula contacts!
Jill Gay
40:54
B.Ryan Phelps, what is your email address?
Rose Wilcher
41:07
https://www.cdc.gov/mmwr/volumes/71/wr/mm7135e1.htm
Omolara Oyinlola
41:34
Omolara Oyinlola, Breakthrough ACTION-Nigeria
Endale Tilahun
42:46
Thanks Deb for the wonderful presentation. Is there a plan to solidify on the experience of global response for HIV and COVID-19 as we prepare to coordinate our global response for MPX?.
Rose Wilcher
43:34
Here is the Lancet paper Stef just mentioned: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30294-4/fulltext
Shawn Aldridge
43:45
What is the level of access in countries with PEPFAR funded key populations programming of antiretrovirals that may be effective in treating symptoms (e.g. TPOXX)?
Deb Goldstein
45:14
@shawn Currently there is limited availability of TPOXX for distribution globally. PEPFAR-funded KP programs currently do not have access to this medication.
Deb Goldstein
57:30
@Endale Thanks for your question. We are building on our investments from HIV and COVID particularly in lab systems, engagement with CHWs, high risk population groups, etc. And we have learned we need to move quickly and deliberately as viruses will not remain in one population group.
Endale Tilahun
01:00:27
Thanks Deb. Well noted.
Brian Pedersen, FHI 360
01:01:13
@Daniel, the media engagement work focused mostly on providing media with correct information about MPX so they didn't go down the path of including myths in their reporting. The focus was not in encouraging them to publish stories about MPX (which is what we typically aim to do when engaging media), but rather equipping them with the right information so they knew how to report on MPX correctly.
Anton Schneider
01:03:22
@Brian - great presentation. How do you think communication with Gen Pop can be best calibrated to avoid stigmatization of KP’s?
Hally Mahler
01:03:46
Anton... let's wait to have that discussion in plenary.
Aung Zayar Paing
01:07:29
Are there any significant mutations/changes in genomic surveillance compared to previous monkeypox in terms of transmissibility and virulence?
Pat Sadate-Ngatchou
01:11:25
Hi Aung, there are more mutations that expected on the MPX virus, and more research is needed to completely understand the genetics and implication of mutations
Pat Sadate-Ngatchou
01:14:09
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901482/
Aung Zayar Paing
01:14:50
Thanks, Pat.
Bhagawan Shrestha
01:19:16
Hi Alex, thanks for great presentation. Is name "Monkeypox" itself fueling fear, stigma and discrimination as well as barrier to access to service?
Hally Mahler
01:21:11
I will ask Alex to respond... but also interesting in the opinions of other participants in this webinar. What do you think about the name "Monkeypox" and does it create stigma?
Carey Johnson
01:23:43
Regarding the name, yes, it has always been problematic and stigmatizing for several historic reasons. Here is a NYT article on efforts to rename it: https://www.nytimes.com/2022/08/23/health/monkeypox-name-stigma.html
Deb Goldstein
01:24:36
Certainly agree that 'monkeypox' is stigmatizing; my understanding is that efforts are underway to rename. WHO also has renamed Congo Basin (Central African) clade as Clade one (I) and the former West African clade as Clade two (II) to reduce stigma. https://www.who.int/news/item/12-08-2022-monkeypox--experts-give-virus-variants-new-names
Michel Daphnee
01:26:25
Do you have models of messages against the stigma of hiv/ MPX ? Or Homophobia/MPX?
Rose Wilcher
01:32:30
https://www.fhi360.org/sites/default/files/media/documents/epic-monkeypox-fact-sheet.pdf
Anton Schneider
01:33:21
Thanks, Brian. Very helpful.
Obinna Onuoha
01:38:22
In Nigeria, there has been consistency with some monkeypox cases presenting with co-infection with chicken pox (varicella zoster) which is unrelated to Pox family. While we see the global trend, perhaps it would be good to focus on the local context and see why this co-infection is reoccurring.
Chris Akolo
01:40:53
Great point, Obinna. This is why we all need to keep in mind that individuals can always present with co-infections. Presenting with one disease does not automatically exclude others and varicella zoster is another example.
Michel Daphnee
01:41:05
Thank you !!!
Rebecca Dirks
01:41:16
Fabulous webinar! Thanks to all the presenters.